This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WALTHAM, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will present at Robert W. Baird & Company's 2012 Health Care Conference on September 5, 2012 at 1:20 p.m. Eastern Time. Eric Bouvier, President and CEO of the Company, will present an overview of BG Medicine and updates on the Company's portfolio of cardiovascular diagnostic tests.
Webcasts of the Company's presentation will be available to the public and accessible by visiting:
http://wsw.com/webcast/baird30/bgmd/ or on the "Investors" section of the Company's website at
www.bg-medicine.com . Replays will be available on the Company's website for 30 days after the initial presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3
® test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORE
TM test, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit
The BG Medicine Inc. logo is available at
CONTACT: Michael W. Rogers
EVP & Chief Financial Officer